Back

Ciraparantag as a potential universal anticoagulant reversal agent

European Heart Journal

14 October 2021
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY BASIC SCIENCE Pharmacology and Pharmacotherapy

Contributors

Noel C Chan
Noel C Chan

Author

Jeffrey I Weitz
Jeffrey I Weitz

Author

Thrombosis & Atherosclerosis Research Institute (TaARI) Hamilton , Canada

You may be interested in
thumbnail
Congress Presentation
Reversal agents to improve safety in patients treated with direct oral anticoagulants (DOACs).
26 August 2022
thumbnail
Congress Presentation
Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis
1 September 2020
thumbnail
Congress Presentation
Anti-Xa/APTT discrepancy in heparinized ImpellaTM-supported cardiogenic shock patients can predict mortality
9 March 2024
thumbnail
Congress Presentation
Patterns and trends of idarucizumab use in an Italian region: a probabilistic record-linkage approach in a real-life setting
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources